The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
P. A. Ellis
Consultant or Advisory Role - Roche/Genentech (U)
Honoraria - Roche/Genentech
C. H. Barrios
Consultant or Advisory Role - Roche
Honoraria - Roche
Y. Im
No relevant relationships to disclose
M. Patre
Employment or Leadership Position - Roche
F. Branle
Employment or Leadership Position - Roche
Other Remuneration - Sanofi
E. A. Perez
Research Funding - Genentech; GlaxoSmithKline